This one has legs and will fly to $3.0 for 13-Nov and then fire on full cylinders to $4 plus. Facts are F'cyte was approved by FDA who have now approved recall to document end to end process and labeling. FDA is actually in soup on legal recall which has led to drop in SP. Why FDA did not meet in middle ground for a approved device even if there are some minor modifications requiring end to end process updates? This will be a grey area between FDA and ATOS and very likely FDA corruption & attitude to small botechs will be played out. Facing saving and every bit effort to prop this SP back upto 80% to 90% is very likely. This will be branded in legal terms as business as usual with small biotechs.
In our days the retailer investor is making a bundle using only momentum stocks.
For ex. this turd might go another 20% next Monday giving those who invested around at $1.8-1.9 a hefty 30% return.
I take it and run to the hill.
This market is controlled by hedge funds, crooked M&M and big gorillas(such as Buffet) benefiting from inside info.
So what is the story behind it? Do you know what the test is looking for? Expand on your deep knowledge of NAF testing in regards to breast cancer, the efficacy of the MASCT device, Dr Quay's history with companies, his wife as the CSO, insurance reimbursement for NAF testing, physician adoption rates, and all the other details your general comment seems to leave out. Also expand on your knowledge of Atossa's pipeline products. Have they done any clinical trials yet or have any been started? Please educate me so I can invest wisely. Thank you.
Investors have already given a 20% boost to the stock yesterday. You however will benefit from staying away from this stock as per your own comments. My advise is to cover your short position (if any) before Nov 14 when the meeting with FDA is scheduled. Next stop is $3.